Industry Research Reports

Home > Reports > Service & Software > Global GMP-grade AAV Vector Manufacturing Service Market Outlook, In‑Depth Analysis & Forecast to 2032

Global GMP-grade AAV Vector Manufacturing Service Market Outlook, In‑Depth Analysis & Forecast to 2032

Industry: Service & Software

Published Date: 2026-07-18

Pages: 148 Pages

Report ld: 6978178

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

GMP-grade AAV Vector Manufacturing Service Market Size(US$)

CAGR 2026-2032

13.2%

Market Size,2032

USD 2,060

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 979 million

Market Forecast in 2032(Value)

US$ 2,060 million

CAGR

13.2%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global GMP-grade AAV Vector Manufacturing Service market is projected to grow from US$ 865 million in 2025 to US$ 2060 million by 2032, at a CAGR of 13.2% (2026-2032), driven by critical product segments and diverse end‑use applications.

GMP-grade AAV vector manufacturing services refer to contract development and manufacturing activities performed under pharmaceutical good manufacturing practice requirements for recombinant adeno-associated viral vectors. The service scope generally includes process development, cell-bank establishment, GMP drug-substance manufacturing, purification, formulation, sterile filtration, fill and finish, quality testing, stability studies, batch release and regulatory support. Common production routes include adherent or suspension HEK293 transient transfection, stable producer-cell platforms and baculovirus-Sf9 systems. Key upstream inputs include GMP-grade transfer plasmids, Rep/Cap plasmids, helper plasmids, production cells, culture media, transfection reagents, nucleases, chromatography resins, filtration consumables, single-use bioreactors and analytical reagents. Major downstream customers include gene therapy developers, biotechnology companies, pharmaceutical companies, hospital translational platforms and research institutions, with applications covering IND submissions, clinical trials, process validation and commercial supply. The industry's overall gross margin is generally estimated at approximately 25%-40%.

The global market currently consists of large integrated CDMOs, specialized AAV manufacturers and regional cell and gene therapy service providers. Large CDMOs compete through global quality systems, multi-site manufacturing networks, commercial-batch experience and integrated fill-and-finish capabilities. Specialized AAV providers differentiate themselves through high-yield HEK293 cells, proprietary plasmid systems, capsid technologies and dedicated AAV facilities. Chinese and other Asia-Pacific providers compete primarily through cost, delivery speed, early-clinical project experience and integrated service offerings. Because clinical programs require consistent technology transfer, comparability, stability data and regulatory documentation, changing suppliers after a program enters GMP manufacturing is substantially more difficult than switching research-grade packaging vendors.

Demand growth is supported by the progression of AAV gene therapy programs into clinical development, indication expansion for approved products, tissue-specific capsid development and increasing outsourcing by small and mid-sized biotechnology companies. Neurological, ophthalmic, neuromuscular and rare metabolic diseases remain important sources of GMP projects, while dual-AAV systems, engineered capsids and gene-editing delivery create additional process-development requirements. Growth is becoming less dependent on the total number of discovery programs and more dependent on whether candidates reach IND submission, advance into later-stage trials and generate repeat manufacturing orders. Tightening expectations for product quality, manufacturing consistency, potency assays and comparability favor providers with integrated analytical, quality and regulatory capabilities.

Manufacturing technology is gradually shifting from adherent culture and highly customized workflows toward suspension culture, platform processes and stable producer-cell systems. Suspension HEK293 transient transfection remains the principal route for clinical-scale expansion, but plasmid and transfection-reagent costs, batch variability and scale-up complexity remain significant. Stable producer cells, dual-plasmid systems, baculovirus-Sf9 platforms and plasmid-free technologies may lower raw-material costs and improve consistency. Downstream competition is moving beyond vector-genome titer toward enrichment of full capsids, removal of empty and partially packaged particles and tighter control of host-cell DNA, host-cell proteins, residual plasmids and replication-competent AAV.

The main constraints include gene therapy financing and pipeline reprioritization, underutilized GMP capacity, high program attrition, elevated production costs and clinical safety events that may delay development. Some facilities built during the earlier investment cycle have experienced slower order ramp-up than initially expected, encouraging CDMOs to compete through platform processes, shorter timelines, flexible batch sizes and more aggressive commercial terms. AAV also faces inherent limitations involving payload capacity, pre-existing neutralizing antibodies, repeat dosing, high-dose toxicity and tissue-targeting efficiency. Lipid nanoparticles, nonviral delivery and other in vivo gene-editing platforms may therefore substitute for AAV in selected indications. Long-term leadership will depend more on productivity, product quality, successful regulatory filings, commercial supply capability and facility utilization than on nominal installed capacity alone.

Report Includes:

This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global GMP-grade AAV Vector Manufacturing Service market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

MARKET SEGMENTATION

By Company

Thermo Fisher Scientific
Lonza
Charles River Laboratories
Catalent
AGC Biologics
SK pharmteco
OXB
Forge Biologics
Viralgen
Andelyn Biosciences
Resilience
Advanced Therapies
IDT Biologika
Matica Bio
Takara Bio
VectorBuilder
GenScript ProBio
PackGene Biotech

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

GMP Drug Substance Manufacturing
GMP Drug Substance and Fill-Finish
End-to-End CMC and Manufacturing

Segment by Application

Biotechnology Companies
Pharmaceutical Companies
Other

Segment by Category

Early Clinical Manufacturing
Late-stage Clinical Manufacturing
PPQ and Commercial Manufacturing

Segment by Division

Adherent HEK293
Suspension HEK293
Baculovirus-Sf9
Other

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the GMP-grade AAV Vector Manufacturing Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential

Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves

Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application

Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers

Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers

Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas

Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges

Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles

Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments

Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels

Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies

Chapter 14: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to GMP-grade AAV Vector Manufacturing Service: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global GMP-grade AAV Vector Manufacturing Service Market Size by Type, 2021 vs 2025 vs 2032

1.2.2 GMP Drug Substance Manufacturing

1.2.3 GMP Drug Substance and Fill-Finish

1.2.4 End-to-End CMC and Manufacturing

1.3 Market Segmentation by Development Stage

1.3.1 Global GMP-grade AAV Vector Manufacturing Service Market Size by Development Stage, 2021 vs 2025 vs 2032

1.3.2 Early Clinical Manufacturing

1.3.3 Late-stage Clinical Manufacturing

1.3.4 PPQ and Commercial Manufacturing

1.4 Market Segmentation by Production Platform

1.4.1 Global GMP-grade AAV Vector Manufacturing Service Market Size by Production Platform, 2021 vs 2025 vs 2032

1.4.2 Adherent HEK293

1.4.3 Suspension HEK293

1.4.4 Baculovirus-Sf9

1.4.5 Other

1.5 Market Segmentation by Application

1.5.1 Global GMP-grade AAV Vector Manufacturing Service Market Size by Application, 2021 vs 2025 vs 2032

1.5.2 Biotechnology Companies

1.5.3 Pharmaceutical Companies

1.5.4 Other

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Executive Summary

2.1 Global GMP-grade AAV Vector Manufacturing Service Revenue Estimates and Forecasts (2021-2032)

2.2 Global GMP-grade AAV Vector Manufacturing Service Revenue by Region

2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032

2.2.2 Historical and Forecasted Revenue by Region (2021-2032)

2.2.3 Global Revenue-Based Market Share by Region (2021-2032)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape

3.1 Global GMP-grade AAV Vector Manufacturing Service Players’ Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2021-2026)

3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Players (2021 vs 2025)

3.2 Global GMP-grade AAV Vector Manufacturing Service Companies Headquarters and Service Footprint

3.3 Key Player Market Share by Product Type

3.3.1 GMP Drug Substance Manufacturing: Market Share by Key Players

3.3.2 GMP Drug Substance and Fill-Finish: Market Share by Key Players

3.3.3 End-to-End CMC and Manufacturing: Market Share by Key Players

3.4 Global GMP-grade AAV Vector Manufacturing Service Market Concentration and Dynamics

3.4.1 Global Market Concentration

3.4.2 Market Entry and Exit Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation

4.1 Global GMP-grade AAV Vector Manufacturing Service Market by Type

4.1.1 Global Revenue by Type (2021-2032)

4.1.2 Global Revenue-Based Market Share by Type (2021-2032)

4.2 Global GMP-grade AAV Vector Manufacturing Service Market by Development Stage

4.2.1 Global Revenue by Development Stage (2021-2032)

4.2.2 Global Revenue-Based Market Share by Development Stage (2021-2032)

4.3 Global GMP-grade AAV Vector Manufacturing Service Market by Production Platform

4.3.1 Global Revenue by Production Platform (2021-2032)

4.3.2 Global Revenue-Based Market Share by Production Platform (2021-2032)

4.4 Key Product Attributes and Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Downstream Applications and Customers

5.1 Global GMP-grade AAV Vector Manufacturing Service Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)

5.1.2 Revenue-Based Market Share by Application (2021-2032)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2021-2032)

6.2 North America Key Players’ Revenue in 2025

6.3 North America GMP-grade AAV Vector Manufacturing Service Market Size by Application (2021-2032)

6.4 North America Growth Accelerators and Market Barriers

6.5 North America GMP-grade AAV Vector Manufacturing Service Market Size by Country

6.5.1 North America Revenue Trends by Country

6.5.2 US

6.5.3 Canada

6.5.4 Mexico

7 Europe

7.1 Europe Market Size (2021-2032)

7.2 Europe Key Players’ Revenue in 2025

7.3 Europe GMP-grade AAV Vector Manufacturing Service Market Size by Application (2021-2032)

7.4 Europe Growth Accelerators and Market Barriers

7.5 Europe GMP-grade AAV Vector Manufacturing Service Market Size by Country

7.5.1 Europe Revenue Trends by Country

7.5.2 Germany

7.5.3 France

7.5.4 U.K.

7.5.5 Italy

7.5.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2021-2032)

8.2 Asia-Pacific Key Players’ Revenue in 2025

8.3 Asia-Pacific GMP-grade AAV Vector Manufacturing Service Market Size by Application (2021-2032)

8.4 Asia-Pacific Growth Accelerators and Market Barriers

8.5 Asia-Pacific GMP-grade AAV Vector Manufacturing Service Market Size by Region

8.5.1 Asia-Pacific Revenue Trends by Region

8.6 China

8.7 Japan

8.8 South Korea

8.9 Australia

8.10 India

8.11 Southeast Asia

8.11.1 Indonesia

8.11.2 Vietnam

8.11.3 Malaysia

8.11.4 Philippines

8.11.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2021-2032)

9.2 Central and South America Key Players’ Revenue in 2025

9.3 Central and South America GMP-grade AAV Vector Manufacturing Service Market Size by Application (2021-2032)

9.4 Central and South America Investment Opportunities and Key Challenges

9.5 Central and South America GMP-grade AAV Vector Manufacturing Service Market Size by Country

9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)

9.5.2 Brazil

9.5.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2021-2032)

10.2 Middle East and Africa Key Players’ Revenue in 2025

10.3 Middle East and Africa GMP-grade AAV Vector Manufacturing Service Market Size by Application (2021-2032)

10.4 Middle East and Africa Investment Opportunities and Key Challenges

10.5 Middle East and Africa GMP-grade AAV Vector Manufacturing Service Market Size by Country

10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)

10.5.2 GCC Countries

10.5.3 Israel

10.5.4 Egypt

10.5.5 South Africa

11 Corporate Profile

11.1 Thermo Fisher Scientific

11.1.1 Thermo Fisher Scientific Corporation Information

11.1.2 Thermo Fisher Scientific Business Overview

11.1.3 Thermo Fisher Scientific GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.1.4 Thermo Fisher Scientific GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.1.5 Thermo Fisher Scientific GMP-grade AAV Vector Manufacturing Service Revenue by Product in 2025

11.1.6 Thermo Fisher Scientific GMP-grade AAV Vector Manufacturing Service Revenue by Application in 2025

11.1.7 Thermo Fisher Scientific GMP-grade AAV Vector Manufacturing Service Revenue by Geographic Area in 2025

11.1.8 Thermo Fisher Scientific GMP-grade AAV Vector Manufacturing Service SWOT Analysis

11.1.9 Thermo Fisher Scientific Recent Developments

11.2 Lonza

11.2.1 Lonza Corporation Information

11.2.2 Lonza Business Overview

11.2.3 Lonza GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.2.4 Lonza GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.2.5 Lonza GMP-grade AAV Vector Manufacturing Service Revenue by Product in 2025

11.2.6 Lonza GMP-grade AAV Vector Manufacturing Service Revenue by Application in 2025

11.2.7 Lonza GMP-grade AAV Vector Manufacturing Service Revenue by Geographic Area in 2025

11.2.8 Lonza GMP-grade AAV Vector Manufacturing Service SWOT Analysis

11.2.9 Lonza Recent Developments

11.3 Charles River Laboratories

11.3.1 Charles River Laboratories Corporation Information

11.3.2 Charles River Laboratories Business Overview

11.3.3 Charles River Laboratories GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.3.4 Charles River Laboratories GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.3.5 Charles River Laboratories GMP-grade AAV Vector Manufacturing Service Revenue by Product in 2025

11.3.6 Charles River Laboratories GMP-grade AAV Vector Manufacturing Service Revenue by Application in 2025

11.3.7 Charles River Laboratories GMP-grade AAV Vector Manufacturing Service Revenue by Geographic Area in 2025

11.3.8 Charles River Laboratories GMP-grade AAV Vector Manufacturing Service SWOT Analysis

11.3.9 Charles River Laboratories Recent Developments

11.4 Catalent

11.4.1 Catalent Corporation Information

11.4.2 Catalent Business Overview

11.4.3 Catalent GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.4.4 Catalent GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.4.5 Catalent GMP-grade AAV Vector Manufacturing Service Revenue by Product in 2025

11.4.6 Catalent GMP-grade AAV Vector Manufacturing Service Revenue by Application in 2025

11.4.7 Catalent GMP-grade AAV Vector Manufacturing Service Revenue by Geographic Area in 2025

11.4.8 Catalent GMP-grade AAV Vector Manufacturing Service SWOT Analysis

11.4.9 Catalent Recent Developments

11.5 AGC Biologics

11.5.1 AGC Biologics Corporation Information

11.5.2 AGC Biologics Business Overview

11.5.3 AGC Biologics GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.5.4 AGC Biologics GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.5.5 AGC Biologics GMP-grade AAV Vector Manufacturing Service Revenue by Product in 2025

11.5.6 AGC Biologics GMP-grade AAV Vector Manufacturing Service Revenue by Application in 2025

11.5.7 AGC Biologics GMP-grade AAV Vector Manufacturing Service Revenue by Geographic Area in 2025

11.5.8 AGC Biologics GMP-grade AAV Vector Manufacturing Service SWOT Analysis

11.5.9 AGC Biologics Recent Developments

11.6 SK pharmteco

11.6.1 SK pharmteco Corporation Information

11.6.2 SK pharmteco Business Overview

11.6.3 SK pharmteco GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.6.4 SK pharmteco GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.6.5 SK pharmteco Recent Developments

11.7 OXB

11.7.1 OXB Corporation Information

11.7.2 OXB Business Overview

11.7.3 OXB GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.7.4 OXB GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.7.5 OXB Recent Developments

11.8 Forge Biologics

11.8.1 Forge Biologics Corporation Information

11.8.2 Forge Biologics Business Overview

11.8.3 Forge Biologics GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.8.4 Forge Biologics GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.8.5 Forge Biologics Recent Developments

11.9 Viralgen

11.9.1 Viralgen Corporation Information

11.9.2 Viralgen Business Overview

11.9.3 Viralgen GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.9.4 Viralgen GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.9.5 Viralgen Recent Developments

11.10 Andelyn Biosciences

11.10.1 Andelyn Biosciences Corporation Information

11.10.2 Andelyn Biosciences Business Overview

11.10.3 Andelyn Biosciences GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.10.4 Andelyn Biosciences GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.10.5 Company Ten Recent Developments

11.11 Resilience

11.11.1 Resilience Corporation Information

11.11.2 Resilience Business Overview

11.11.3 Resilience GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.11.4 Resilience GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.11.5 Resilience Recent Developments

11.12 Advanced Therapies

11.12.1 Advanced Therapies Corporation Information

11.12.2 Advanced Therapies Business Overview

11.12.3 Advanced Therapies GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.12.4 Advanced Therapies GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.12.5 Advanced Therapies Recent Developments

11.13 IDT Biologika

11.13.1 IDT Biologika Corporation Information

11.13.2 IDT Biologika Business Overview

11.13.3 IDT Biologika GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.13.4 IDT Biologika GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.13.5 IDT Biologika Recent Developments

11.14 Matica Bio

11.14.1 Matica Bio Corporation Information

11.14.2 Matica Bio Business Overview

11.14.3 Matica Bio GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.14.4 Matica Bio GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.14.5 Matica Bio Recent Developments

11.15 Takara Bio

11.15.1 Takara Bio Corporation Information

11.15.2 Takara Bio Business Overview

11.15.3 Takara Bio GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.15.4 Takara Bio GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.15.5 Takara Bio Recent Developments

11.16 VectorBuilder

11.16.1 VectorBuilder Corporation Information

11.16.2 VectorBuilder Business Overview

11.16.3 VectorBuilder GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.16.4 VectorBuilder GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.16.5 VectorBuilder Recent Developments

11.17 GenScript ProBio

11.17.1 GenScript ProBio Corporation Information

11.17.2 GenScript ProBio Business Overview

11.17.3 GenScript ProBio GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.17.4 GenScript ProBio GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.17.5 GenScript ProBio Recent Developments

11.18 PackGene Biotech

11.18.1 PackGene Biotech Corporation Information

11.18.2 PackGene Biotech Business Overview

11.18.3 PackGene Biotech GMP-grade AAV Vector Manufacturing Service Product Features and Attributes

11.18.4 PackGene Biotech GMP-grade AAV Vector Manufacturing Service Revenue and Gross Margin (2021-2026)

11.18.5 PackGene Biotech Recent Developments

12 GMP-grade AAV Vector Manufacturing Service Value Chain and Ecosystem Analysis

12.1 GMP-grade AAV Vector Manufacturing Service Value Chain (Ecosystem Structure)

12.2 Upstream Analysis

12.2.1 Key Technologies, Platforms and Infrastructure

12.3 Midstream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 GMP-grade AAV Vector Manufacturing Service Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global GMP-grade AAV Vector Manufacturing Service Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global GMP-grade AAV Vector Manufacturing Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Table 2. Global GMP-grade AAV Vector Manufacturing Service Market Size Growth Rate by Development Stage, 2021 vs 2025 vs 2032 (US$ Million)

Table 3. Global GMP-grade AAV Vector Manufacturing Service Market Size Growth Rate by Production Platform, 2021 vs 2025 vs 2032 (US$ Million)

Table 4. Global GMP-grade AAV Vector Manufacturing Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Table 5. Global GMP-grade AAV Vector Manufacturing Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 6. Global GMP-grade AAV Vector Manufacturing Service Revenue by Region (US$ Million), 2021-2026

Table 7. Global GMP-grade AAV Vector Manufacturing Service Revenue by Region (US$ Million), 2027-2032

Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 9. Global GMP-grade AAV Vector Manufacturing Service Revenue by Players (US$ Million), 2021-2026

Table 10. Global GMP-grade AAV Vector Manufacturing Service Revenue-Based Market Share by Players (2021-2026)

Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)

Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on GMP-grade AAV Vector Manufacturing Service Revenue, 2025

Table 13. Global GMP-grade AAV Vector Manufacturing Service Average Gross Margin (%) by Player (2021 vs 2025)

Table 14. Global GMP-grade AAV Vector Manufacturing Service Companies Headquarters

Table 15. Global GMP-grade AAV Vector Manufacturing Service Market Concentration Ratio (CR5)

Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis

Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 18. Global GMP-grade AAV Vector Manufacturing Service Revenue by Type (US$ Million), 2021-2026

Table 19. Global GMP-grade AAV Vector Manufacturing Service Revenue by Type (US$ Million), 2027-2032

Table 20. Global GMP-grade AAV Vector Manufacturing Service Revenue by Development Stage (US$ Million), 2021-2026

Table 21. Global GMP-grade AAV Vector Manufacturing Service Revenue by Development Stage (US$ Million), 2027-2032

Table 22. Global GMP-grade AAV Vector Manufacturing Service Revenue by Production Platform (US$ Million), 2021-2026

Table 23. Global GMP-grade AAV Vector Manufacturing Service Revenue by Production Platform (US$ Million), 2027-2032

Table 24. Key Product Attributes and Differentiation

Table 25. Global GMP-grade AAV Vector Manufacturing Service Revenue by Application (US$ Million), 2021-2026

Table 26. Global GMP-grade AAV Vector Manufacturing Service Revenue by Application (US$ Million), 2027-2032

Table 27. GMP-grade AAV Vector Manufacturing Service High-Growth Sectors Demand CAGR (2026-2032)

Table 28. Top Customers by Region

Table 29. Top Customers by Application

Table 30. North America GMP-grade AAV Vector Manufacturing Service Growth Accelerators and Market Barriers

Table 31. North America GMP-grade AAV Vector Manufacturing Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 32. Europe GMP-grade AAV Vector Manufacturing Service Growth Accelerators and Market Barriers

Table 33. Europe GMP-grade AAV Vector Manufacturing Service Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 34. Asia-Pacific GMP-grade AAV Vector Manufacturing Service Growth Accelerators and Market Barriers

Table 35. Asia-Pacific GMP-grade AAV Vector Manufacturing Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Central and South America GMP-grade AAV Vector Manufacturing Service Investment Opportunities and Key Challenges

Table 37. Central and South America GMP-grade AAV Vector Manufacturing Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 38. Middle East and Africa GMP-grade AAV Vector Manufacturing Service Investment Opportunities and Key Challenges

Table 39. Middle East and Africa GMP-grade AAV Vector Manufacturing Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 40. Thermo Fisher Scientific Corporation Information

Table 41. Thermo Fisher Scientific Description and Major Businesses

Table 42. Thermo Fisher Scientific Product Features and Attributes

Table 43. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2021-2026)

Table 44. Thermo Fisher Scientific Revenue Proportion by Product in 2025

Table 45. Thermo Fisher Scientific Revenue Proportion by Application in 2025

Table 46. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2025

Table 47. Thermo Fisher Scientific GMP-grade AAV Vector Manufacturing Service SWOT Analysis

Table 48. Thermo Fisher Scientific Recent Developments

Table 49. Lonza Corporation Information

Table 50. Lonza Description and Major Businesses

Table 51. Lonza Product Features and Attributes

Table 52. Lonza Revenue (US$ Million) and Gross Margin (2021-2026)

Table 53. Lonza Revenue Proportion by Product in 2025

Table 54. Lonza Revenue Proportion by Application in 2025

Table 55. Lonza Revenue Proportion by Geographic Area in 2025

Table 56. Lonza GMP-grade AAV Vector Manufacturing Service SWOT Analysis

Table 57. Lonza Recent Developments

Table 58. Charles River Laboratories Corporation Information

Table 59. Charles River Laboratories Description and Major Businesses

Table 60. Charles River Laboratories Product Features and Attributes

Table 61. Charles River Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)

Table 62. Charles River Laboratories Revenue Proportion by Product in 2025

Table 63. Charles River Laboratories Revenue Proportion by Application in 2025

Table 64. Charles River Laboratories Revenue Proportion by Geographic Area in 2025

Table 65. Charles River Laboratories GMP-grade AAV Vector Manufacturing Service SWOT Analysis

Table 66. Charles River Laboratories Recent Developments

Table 67. Catalent Corporation Information

Table 68. Catalent Description and Major Businesses

Table 69. Catalent Product Features and Attributes

Table 70. Catalent Revenue (US$ Million) and Gross Margin (2021-2026)

Table 71. Catalent Revenue Proportion by Product in 2025

Table 72. Catalent Revenue Proportion by Application in 2025

Table 73. Catalent Revenue Proportion by Geographic Area in 2025

Table 74. Catalent GMP-grade AAV Vector Manufacturing Service SWOT Analysis

Table 75. Catalent Recent Developments

Table 76. AGC Biologics Corporation Information

Table 77. AGC Biologics Description and Major Businesses

Table 78. AGC Biologics Product Features and Attributes

Table 79. AGC Biologics Revenue (US$ Million) and Gross Margin (2021-2026)

Table 80. AGC Biologics Revenue Proportion by Product in 2025

Table 81. AGC Biologics Revenue Proportion by Application in 2025

Table 82. AGC Biologics Revenue Proportion by Geographic Area in 2025

Table 83. AGC Biologics GMP-grade AAV Vector Manufacturing Service SWOT Analysis

Table 84. AGC Biologics Recent Developments

Table 85. SK pharmteco Corporation Information

Table 86. SK pharmteco Description and Major Businesses

Table 87. SK pharmteco Product Features and Attributes

Table 88. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026)

Table 89. SK pharmteco Recent Developments

Table 90. OXB Corporation Information

Table 91. OXB Description and Major Businesses

Table 92. OXB Product Features and Attributes

Table 93. OXB Revenue (US$ Million) and Gross Margin (2021-2026)

Table 94. OXB Recent Developments

Table 95. Forge Biologics Corporation Information

Table 96. Forge Biologics Description and Major Businesses

Table 97. Forge Biologics Product Features and Attributes

Table 98. Forge Biologics Revenue (US$ Million) and Gross Margin (2021-2026)

Table 99. Forge Biologics Recent Developments

Table 100. Viralgen Corporation Information

Table 101. Viralgen Description and Major Businesses

Table 102. Viralgen Product Features and Attributes

Table 103. Viralgen Revenue (US$ Million) and Gross Margin (2021-2026)

Table 104. Viralgen Recent Developments

Table 105. Andelyn Biosciences Corporation Information

Table 106. Andelyn Biosciences Description and Major Businesses

Table 107. Andelyn Biosciences Product Features and Attributes

Table 108. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)

Table 109. Andelyn Biosciences Recent Developments

Table 110. Resilience Corporation Information

Table 111. Resilience Description and Major Businesses

Table 112. Resilience Product Features and Attributes

Table 113. Resilience Revenue (US$ Million) and Gross Margin (2021-2026)

Table 114. Resilience Recent Developments

Table 115. Advanced Therapies Corporation Information

Table 116. Advanced Therapies Description and Major Businesses

Table 117. Advanced Therapies Product Features and Attributes

Table 118. Advanced Therapies Revenue (US$ Million) and Gross Margin (2021-2026)

Table 119. Advanced Therapies Recent Developments

Table 120. IDT Biologika Corporation Information

Table 121. IDT Biologika Description and Major Businesses

Table 122. IDT Biologika Product Features and Attributes

Table 123. IDT Biologika Revenue (US$ Million) and Gross Margin (2021-2026)

Table 124. IDT Biologika Recent Developments

Table 125. Matica Bio Corporation Information

Table 126. Matica Bio Description and Major Businesses

Table 127. Matica Bio Product Features and Attributes

Table 128. Matica Bio Revenue (US$ Million) and Gross Margin (2021-2026)

Table 129. Matica Bio Recent Developments

Table 130. Takara Bio Corporation Information

Table 131. Takara Bio Description and Major Businesses

Table 132. Takara Bio Product Features and Attributes

Table 133. Takara Bio Revenue (US$ Million) and Gross Margin (2021-2026)

Table 134. Takara Bio Recent Developments

Table 135. VectorBuilder Corporation Information

Table 136. VectorBuilder Description and Major Businesses

Table 137. VectorBuilder Product Features and Attributes

Table 138. VectorBuilder Revenue (US$ Million) and Gross Margin (2021-2026)

Table 139. VectorBuilder Recent Developments

Table 140. GenScript ProBio Corporation Information

Table 141. GenScript ProBio Description and Major Businesses

Table 142. GenScript ProBio Product Features and Attributes

Table 143. GenScript ProBio Revenue (US$ Million) and Gross Margin (2021-2026)

Table 144. GenScript ProBio Recent Developments

Table 145. PackGene Biotech Corporation Information

Table 146. PackGene Biotech Description and Major Businesses

Table 147. PackGene Biotech Product Features and Attributes

Table 148. PackGene Biotech Revenue (US$ Million) and Gross Margin (2021-2026)

Table 149. PackGene Biotech Recent Developments

Table 150. Technologies, Platforms and Infrastructure

Table 151. Distributors List

Table 152. Market Trends and Market Evolution

Table 153. Market Drivers and Opportunities

Table 154. Market Challenges, Risks, and Restraints

Table 155. Research Programs/Design for This Report

Table 156. Key Data Information from Secondary Sources

Table 157. Key Data Information from Primary Sources

List of Figures

Figure 1. Global GMP-grade AAV Vector Manufacturing Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Figure 2. GMP Drug Substance Manufacturing Product Picture

Figure 3. GMP Drug Substance and Fill-Finish Product Picture

Figure 4. End-to-End CMC and Manufacturing Product Picture

Figure 5. Global GMP-grade AAV Vector Manufacturing Service Market Size Growth Rate by Development Stage, 2021 vs 2025 vs 2032 (US$ Million)

Figure 6. Early Clinical Manufacturing Product Picture

Figure 7. Late-stage Clinical Manufacturing Product Picture

Figure 8. PPQ and Commercial Manufacturing Product Picture

Figure 9. Global GMP-grade AAV Vector Manufacturing Service Market Size Growth Rate by Production Platform, 2021 vs 2025 vs 2032 (US$ Million)

Figure 10. Adherent HEK293 Product Picture

Figure 11. Suspension HEK293 Product Picture

Figure 12. Baculovirus-Sf9 Product Picture

Figure 13. Other Product Picture

Figure 14. Global GMP-grade AAV Vector Manufacturing Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Figure 15. Biotechnology Companies

Figure 16. Pharmaceutical Companies

Figure 17. Other

Figure 18. GMP-grade AAV Vector Manufacturing Service Report Years Considered

Figure 19. Global GMP-grade AAV Vector Manufacturing Service Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 20. Global GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 21. Global GMP-grade AAV Vector Manufacturing Service Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Figure 22. Global GMP-grade AAV Vector Manufacturing Service Revenue-Based Market Share by Region (2021-2032)

Figure 23. Global GMP-grade AAV Vector Manufacturing Service Revenue-Based Market Share Ranking (2025)

Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025)

Figure 25. GMP Drug Substance Manufacturing Revenue-Based Market Share by Player in 2025

Figure 26. GMP Drug Substance and Fill-Finish Revenue-Based Market Share by Player in 2025

Figure 27. End-to-End CMC and Manufacturing Revenue-Based Market Share by Player in 2025

Figure 28. Global GMP-grade AAV Vector Manufacturing Service Revenue-Based Market Share by Type (2021-2032)

Figure 29. Global GMP-grade AAV Vector Manufacturing Service Revenue-Based Market Share by Development Stage (2021-2032)

Figure 30. Global GMP-grade AAV Vector Manufacturing Service Revenue-Based Market Share by Production Platform (2021-2032)

Figure 31. Global GMP-grade AAV Vector Manufacturing Service Revenue-Based Market Share by Application (2021-2032)

Figure 32. North America GMP-grade AAV Vector Manufacturing Service Revenue YoY (US$ Million), 2021-2032

Figure 33. North America Top 5 Players GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) in 2025

Figure 34. North America GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) by Application (2021-2032)

Figure 35. US GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 36. Canada GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 37. Mexico GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 38. Europe GMP-grade AAV Vector Manufacturing Service Revenue YoY (US$ Million), 2021-2032

Figure 39. Europe Top 5 Players GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) in 2025

Figure 40. Europe GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) by Application (2021-2032)

Figure 41. Germany GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 42. France GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 43. U.K. GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 44. Italy GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 45. Russia GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 46. Asia-Pacific GMP-grade AAV Vector Manufacturing Service Revenue YoY (US$ Million), 2021-2032

Figure 47. Asia-Pacific Top 8 Players GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) in 2025

Figure 48. Asia-Pacific GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) by Application (2021-2032)

Figure 49. Indonesia GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 50. Japan GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 51. South Korea GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 52. Australia GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 53. India GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 54. Indonesia GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 55. Vietnam GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 56. Malaysia GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 57. Philippines GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 58. Singapore GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 59. Central and South America GMP-grade AAV Vector Manufacturing Service Revenue YoY (US$ Million), 2021-2032

Figure 60. Central and South America Top 5 Players GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) in 2025

Figure 61. Central and South America GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) by Application (2021-2032)

Figure 62. Brazil GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 63. Argentina GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 64. Middle East and Africa GMP-grade AAV Vector Manufacturing Service Revenue YoY (US$ Million), 2021-2032

Figure 65. Middle East and Africa Top 5 Players GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) in 2025

Figure 66. Middle East and Africa GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million) by Application (2021-2032)

Figure 67. GCC Countries GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 68. Israel GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 69. Egypt GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 70. South Africa GMP-grade AAV Vector Manufacturing Service Revenue (US$ Million), 2021-2032

Figure 71. GMP-grade AAV Vector Manufacturing Service Value Chain Mapping

Figure 72. Channels of Distribution (Direct Vs Distribution)

Figure 73. Bottom-up and Top-down Approaches for This Report

Figure 74. Data Triangulation

Figure 75. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global GMP-grade AAV Vector Manufacturing Service market? zhanKai

The top companies in the global GMP-grade AAV Vector Manufacturing Service market are Thermo Fisher Scientific、Lonza、Charles River Laboratories.

What is the annual compound growth rate of the global GMP-grade AAV Vector Manufacturing Service market size from 2026 to 2032? shouQi

What was the global market size of GMP-grade AAV Vector Manufacturing Service in 2026? shouQi

Which region is expected to have the highest market share? shouQi

What was the global market size of GMP-grade AAV Vector Manufacturing Service in 2032? shouQi

Related Reports

GMP-grade AAV Vector Manufacturing Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for GMP-grade AAV Vector Manufacturing Service was estimated to be worth US$ 865 million in 2025 and is projected to reach US$ 2060 million, growing at a CAGR of 13.2% from 2026 to 2032.
Published Date: 2026-07-18
Pages: 124
USD 3950.00
(Single User License)
Global GMP-grade AAV Vector Manufacturing Service Market Research Report 2026
The global GMP-grade AAV Vector Manufacturing Service market was valued at US$ 865 million in 2025 and is anticipated to reach US$ 2060 million by 2032, at a CAGR of 13.2% from 2026 to 2032.
Published Date: 2026-07-18
Pages: 129
USD 2900.00
(Single User License)
Global GMP-grade AAV Vector Manufacturing Service Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global GMP-grade AAV Vector Manufacturing Service market size was US$ 865 million in 2025 and is forecast to reach a readjusted size of US$ 2060 million by 2032 with a CAGR of 13.2% during the forecast period 2026-2032.
Published Date: 2026-07-18
Pages: 132
USD 4250.00
(Single User License)

GMP-grade AAV Vector Manufacturing Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for GMP-grade AAV Vector Manufacturing Service was estimated to be worth US$ 865 million in 2025 and is projected to reach US$ 2060 million, growing at a CAGR of 13.2% from 2026 to 2032.
Published: 2026-07-18
Pages: 124
USD 3950.00 (Single User License)
Global GMP-grade AAV Vector Manufacturing Service Market Research Report 2026
The global GMP-grade AAV Vector Manufacturing Service market was valued at US$ 865 million in 2025 and is anticipated to reach US$ 2060 million by 2032, at a CAGR of 13.2% from 2026 to 2032.
Published: 2026-07-18
Pages: 129
USD 2900.00 (Single User License)
Global GMP-grade AAV Vector Manufacturing Service Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global GMP-grade AAV Vector Manufacturing Service market size was US$ 865 million in 2025 and is forecast to reach a readjusted size of US$ 2060 million by 2032 with a CAGR of 13.2% during the forecast period 2026-2032.
Published: 2026-07-18
Pages: 132
USD 4250.00 (Single User License)